Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment

World Journal of Gastroenterology

Volumn 15, Issue 19, 2009, Pages 2314-2328

  Czaja, Albert J ^a,b   Bayraktar, Yusuf ^a,b  

^a MAYO CLINIC   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Non classical phenotypes; Scoring systems; Treatment strategies

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HLA DR ANTIGEN; LIVER KIDNEY MICROSOME TYPE 1 ANTIBODY; MERCAPTOPURINE; MICROSOME ANTIBODY; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALOPECIA; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE HEPATITIS; CELL THERAPY; CHOLANGIOGRAPHY; CLINICAL CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; ETHNIC DIFFERENCE; HEPATITIS A; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER FUNCTION TEST; LIVER NECROSIS; NAUSEA; NONALCOHOLIC FATTY LIVER; PANCREATITIS; PHENOTYPE; REMISSION; SALVAGE THERAPY; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; TURKEY (REPUBLIC); UNSPECIFIED SIDE EFFECT; VACCINATION; VOMITING;

EID: 67651241981     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.2314     Document Type: Article

References (215)

1. Bongiovanni AM, Eisenmenger WJ. Adrenal cortical metabolism in chronic liver disease. J Clin Endocrinol Metab 1951; 11: 152-172
2. Bearn AG, Kunkel HG, Slater RJ. The problem of chronic liver disease in young women. Am J Med 1956; 21: 3-15
3. Cowling DC, Mackay IR, Taft LI. Lupoid hepatitis. Lancet 1956; 271: 1323-1326
4. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 1993; 18: 342-352
5. Taft LI, Mackay IR, Cowling DC. Autoclasia: a perpetuacting mechanism in hepatitis. Gastroenterology 1960; 38: 563-566
6. Cochrane AM, Moussouros A, Thomsom AD, Eddleston AL, Wiiliams R. Antibody-dependent cell-mediated (K cell) cytotoxicity against isolated hepatocytes in chronic active hepatitis. Lancet 1976; 1: 441-444
7. Hodgson HJ, Wands JR, Isselbacher KJ. Alteration in suppressor cell activity in chronic active hepatitis. Proc Natl Acad Sci USA 1978; 75: 1549-1553
8. Frazer IH, Mackay IR. T lymphocyte subpopulations defined by two sets of monoclonal antibodies in chronic active hepatitis and systemic lupus erythematosus. Clin Exp Immunol 1982; 50: 107-114
9. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005
10. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
11. Czaja AJ. Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 2005; 51: 313-333
12. Crapper RM, Bhathal PS, Mackay IR, Frazer IH. 'Acute' autoimmune hepatitis. Digestion 1986; 34: 216-225
13. Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989; 11: 303-307
14. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994; 21: 866-871
15. Kanda T, Yokosuka O, Hirasawa Y, Imazeki F, Nagao K, Suzuki Y, Saisho H. Acute-onset autoimmune hepatitis resembling acute hepatitis: a case report and review of reported cases. Hepatogastroenterology 2005; 52: 1233-1235
16. Maggiore G, Porta G, Bernard O, Hadchouel M, Alvarez F, Homberg JC, Alagille D. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr 1990; 116: 280-282
17. Herzog D, Rasquin-Weber AM, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol 1997; 27: 578-582
18. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004; 2: 625-631
19. Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, Sakaguchi K, Shiratori Y. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006; 23: 1347-1353
20. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002; 35: 75-81
21. Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 53-62
22. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2008; Epub ahead of print
23. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 1222-1227
24. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-857
25. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004; 39: 1631-1638
26. Schalm SW, Korman MG, Summerskill WH, Czaja AJ, Baggenstoss AH. Severe chronic active liver disease. Prognostic significance of initial morphologic patterns. Am J Dig Dis 1977; 22: 973-980
27. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981; 304: 5-9
28. Bittencourt PL, Farias AQ, Porta G, Cançado EL, Miura I, Pugliese R, Kalil J, Goldberg AC, Carrilho FJ. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008; 42: 300-305
29. Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 2008; 25: 219-239
30. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394-401
31. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993; 104: 1755-1761
32. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci 2007; 52: 2433-2437
33. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997; 113: 664-668
34. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002; 97: 2670-2673
35. Okano N, Yamamoto K, Sakaguchi K, Miyake Y, Shimada N, Hakoda T, Terada R, Baba S, Suzuki T, Tsuji T. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003; 25: 263-270
36. Hofer H, Oesterreicher C, Wrba F, Ferenci P, Penner E. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol 2006; 59: 246-249
37. Zen Y, Notsumata K, Tanaka N, Nakanuma Y. Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 2007; 38: 1669-1675
38. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminology. Liver 1984; 4: 105-116
39. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 1993; 18: 10-15
40. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31: 1231-1238
41. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34: 659-665
42. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver Int 2004; 24: 322-329
43. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol 2001; 96: 3390-3394
44. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol 2002; 97: 2402-2407
45. Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002; 50: 713-717
46. Gohar S, Desai D, Joshi A, Bhaduri A, Deshpande R, Balkrishna C, Chawla M, Rodrigues C, Joshi VR. Autoimmune hepatitis: a study of 50 patients. Indian J Gastroenterol 2003; 22: 140-142
47. D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR. An unusual form of autoimmune hepatitis in young Somalian men. Liver Int 2005; 25: 325-330
48. Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J 1998; 17: 297-300
49. Ichai P, Duclos-Vallée JC, Guettier C, Hamida SB, Antonini T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003
50. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007; 13: 953-955
51. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, Schoenfield LJ. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833
52. Summerskill WH, Korman MG, Ammon HV, Baggenstoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 876-883
53. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981-985
54. Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001; 32: 428-430
55. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 646-652
56. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar SM, Sedaghat M, Alimohamadi SM. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 547-551
57. Schalm SW, Ammon HV, Summerskill WH. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976; 8: 221-227
58. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-1145
59. Czaja AJ, Davis GL, Ludwig J, Taswell HF. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-627
60. Czaja AJ, Ammon HV, Summerskill WH. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980; 78: 518-523
61. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston AL, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-689
62. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 92: 215-219
63. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-897
64. Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-515
65. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-176
66. Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008; 48: 1540-1548
67. Kanzler S, Gerken G, Löhr H, Galle PR, Meyer zum Büschenfelde KH, Lohse AW. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001; 34: 354-355
68. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-1516
69. Miyake Y, Iwasaki Y, Terada R, Takagi S, Okamaoto R, Ikeda H, Sakai N, Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori Y. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-957
70. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-1012
71. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8: 781-784
72. Czaja AJ. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044-1049
73. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-963
74. Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 2008; 103: 138-146
75. Manns MP, Bahr MJ, Woynarowski M, Kreisel W, Oren R, Günther R, Hultcrantz R, Proels M, Rust C, Spengler U, Szalay F. Budesonide 3 mg TID is superior to prednisolone in combination with azathioprine in the treatment of autoimmune hepatitis (abstract). J Hepatol 2008; 48 suppl 2: S369-S370
76. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002; 6: 825-850, ix
77. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 202-214
78. Czaja AJ. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007; 1: 113-128
79. Czaja AJ. Evolving concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Minerva Gastroenterol Dietol 2007; 53: 43-78
80. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-497
81. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995; 19: 699-708
82. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85: 713-717
83. Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc 1982; 57: 303-309
84. Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol Res 2008; 38: 784-789
85. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448-453
86. Tan P, Marotta P, Ghent C, Adams P. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int 2005; 25: 728-733
87. De Groote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978; 19: 510-513
88. Koretz RL, Lewin KJ, Higgins J, Fagen ND, Gitnick GL. Chronic active hepatitis. Who meets treatment criteria? Dig Dis Sci 1980; 25: 695-699
89. Hodges JR, Millward-Sadler GH, Wright R. Chronic active hepatitis: the spectrum of disease. Lancet 1982; 1: 550-552
90. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185
91. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737
92. Misdraji J, Thiim M, Graeme-Cook FM. Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol 2004; 28: 471-478
93. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-1832
94. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2004; 99: 1316-1320
95. Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 1997; 25: 538-540
96. Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM, Borsatti A, Bertolotti M, Cassani F, Bagni A, Muratori P, Ganazzi D, Bianchi FB, Carulli N. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003; 48: 2173-2181
97. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol 2007; 5: 898-907
98. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 2005; 40: 127-164
99. Czaja AJ. Autoimmune hepatitis. Part B: diagnosis. Expert Rev Gastroenterol Hepatol 2007; 1: 129-143
100. Czaja AJ, Hay JE, Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc 1990; 65: 23-30
101. Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, Porta G, Nishioka M, Simon T, Daehnrich C, Schlumberger W, Galle PR, Lohse AW. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-264
102. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002; 35: 475-483
103. Targan SR, Landers C, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995; 108: 1159-1166
104. Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, Muratori L, Bianchi FB. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25: 1105-1107
105. Volta U, De Franceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M, Bianchi FB, Czaja AJ. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998; 43: 2190-2195
106. Kaukinen K, Halme L, Collin P, Färkkilä M, Mäki M, Vehmanen P, Partanen J, Höckerstedt K. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002; 122: 881-888
107. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004; 2: 107-112
108. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986; 31: 705-711
109. Muratori P, Muratori L, Gershwin ME, Czaja AJ, Pappas G, MacCariello S, Granito A, Cassani F, Loria P, Lenzi M, Bianchi FB. 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol 2004; 135: 154-158
110. Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, Takahashi S. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol 2006; 21: 1448-1454
111. O'Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48: 550-556
112. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 1047-1053
113. Mishima S, Omagari K, Ohba K, Kadokawa Y, Masuda J, Mishima R, Kinoshita H, Hayashida K, Isomoto H, Shikuwa S, Mizuta Y, Kohno S. Clinical implications of antimitochondrial antibodies in type 1 autoimmune hepatitis: a longitudinal study. Hepatogastroenterology 2008; 55: 221-227
114. Leung PS, Rossaro L, Davis PA, Park O, Tanaka A, Kikuchi K, Miyakawa H, Norman GL, Lee W, Gershwin ME. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 2007; 46: 1436-1442
115. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-553
116. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-331
117. Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008; 47: 949-957
118. Sahni VA, Mortele KJ. Magnetic resonance cholangiopa ncreatography: current use and future applications. Clin Gastroenterol Hepatol 2008; 6: 967-977
119. Lewin M, Vilgrain V, Ozenne V, Lemoine M, Wendum D, Paradis V, Ziol M, Beaugrand M, Poupon R, Valla D, Chazouilleres O, Corpechot C. MRI abnormalities of bile ducts in adults with autoimmune hepatitis: myth or reality? Results of a controlled prospective study (abstract). Hepatology (Suppl) 2008; 48: 421A
120. Gohlke F, Lohse AW, Dienes HP, Löhr H, Märker-Hermann E, Gerken G, Meyer zum Büschenfelde KH. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol 1996; 24: 699-705
121. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998; 28: 360-365
122. McNair AN, Moloney M, Portmann BC, Williams R, McFarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998; 93: 777-784
123. Floreani A, Rizzotto ER, Ferrara F, Carderi I, Caroli D, Blasone L, Baldo V. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 1516-1522
124. Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008; 28: 209-220
125. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002; 6: 799-824
126. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002; 6: 685-705
127. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33: 99-103
128. Werner M, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergquist A, Wallerstedt S, Sandberg-Gertzén H, Hultcrantz R, Sangfelt P, Weiland O, Danielsson A. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232-1240
129. Czaja AJ, dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci 1998; 43: 2149-2155
130. Czaja AJ, Carpenter HA, Sant rach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502-1507
131. Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317-323
132. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 2051-2057
133. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816-822
134. Tong MJ, Hsieh J, Blatt LM. Demographics, treatment and a predictive model of survival in a population of chronic auto- immune hepatitis patients (abstract). Hepatology 1998; 28: 549A
135. Heneghan MA, Kosar Y, McDougall NI, Portmann B, McFarlane IG, Harrison PM. Characteristics and outcome of a large male cohort with autoimmune hepatitis: Male sex as a favorable prognostic indicator: Treat-ment response and outcome (abstract). Gastroenterology 2000; 118: A1009
136. Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008; 48: 140-147
137. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 2007; 46: 1828-1835
138. Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: Biological, cultural, or socioeconomic factors. Hepatology 2008; 47: 1058-1066
139. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, Aoshima M, Hasegawa T, Makino I. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 490-495
140. Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, Donaldson PT. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002; 37: 302-308
141. Chung HV, Riley M, Ho JK, Leung B, Jevon GP, Arbour LT, Barker C, Schreiber R, Yoshida EM. Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol 2007; 21: 565-568
142. Minuk GY, Liu S, Kaita K, Wong S, Renner E, Rempel J, Uhanova J. Autoimmune hepatitis in a North American Aboriginal/First Nations population. Can J Gastroenterol 2008; 22: 829-834
143. Scott JD, Garland N. Chronic liver disease in Aboriginal North Americans. World J Gastroenterol 2008; 14: 4607-4615
144. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002; 6: 707-725
145. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 379-388
146. Siegel AB, McBride RB, El-Serag HB, Hershman DL, Brown RS Jr, Renz JF, Emond J, Neugut AI. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008; 103: 120-127
147. Flores YN, Yee HF Jr, Leng M, Escarce JJ, Bastani R, Salmerón J, Morales LS. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol 2008; 103: 2231-2238
148. Günsar F, Akarca US, Ersöz G, Karasu Z, Yüce G, Batur Y. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepatogastroenterology 2002; 49: 1195-1200
149. Kaymakoglu S, Cakaloglu Y, Demir K, Türkoglu S, Badur S, Gürel S, Beşişik F, Cevikbaş U, Okten A. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol 1998; 28: 78-83
150. Balaban YH, Batman F, Us D, Hascelik G, Bayraktar Y. Serum hepatocyte growth factor in autoimmune and hepatitis B-associated liver diseases. Indian J Gastroenterol 2007; 26: 192-193
151. Usta Y, Gurakan F, Akcoren Z, Ozen S. An overlap syndrome involving autoimmune hepatitis and systemic lupus erythematosus in childhood. World J Gastroenterol 2007; 13: 2764-2767
152. Kayacetin E, Köklü S, Temuçin T. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with unusual initial presentation as fulminant hepatic failure. Dig Liver Dis 2004; 36: 419-422
153. Cindoruk M, Yetkin I, Karakan T, Kandilci U. The prevalence of autoimmune hepatitis in Hashimoto's thyroiditis in a Turkish population. Acta Gastroenterol Belg 2002; 65: 143-145
154. Arslan N, Büyükgebiz B, Oztürk Y, Ozer E. The prevalence of liver function abnormalities in pediatric celiac disease patients and its relation with intestinal biopsy findings. Acta Gastroenterol Belg 2005; 68: 424-427
155. Kocaman O, Aygun C, Gurbuz Y, Cefle A, Konduk T, Senturk O, Celebi A, Hulagu S. Burst of autoimmunity with the emergence of primary Sjogren syndrome, cholestatic autoimmune hepatitis and latent autoimmune diabetes of adults (LADA). South Med J 2006; 99: 1014-1015
156. Soy M, Guldiken S, Arikan E, Altun BU, Tugrul A. Frequency of rheumatic diseases in patients with autoimmune thyroid disease. Rheumatol Int 2007; 27: 575-577
157. Tabak F, Ozdemir F, Tabak O, Erer B, Tahan V, Ozaras R. Autoimmune hepatitis induced by the prolonged hepatitis A virus infection. Ann Hepatol 2008; 7: 177-179
158. Selimoglu MA, Ertekin V. Autoimmune hepatitis triggered by Brucella infection or doxycycline or both. Int J Clin Pract 2003; 57: 639-641
159. Kocaman O, Hulagu S, Senturk O. Echinacea-induced severe acute hepatitis with features of cholestatic autoimmune hepatitis. Eur J Intern Med 2008; 19: 148
160. Kacar S, Akdogan M, Koşar Y, Parlak E, Sasmaz N, Oguz P, Aydog G. Estrogen and cyproterone acetate combination-induced autoimmune hepatitis. J Clin Gastroenterol 2002; 35: 98-100
161. Koşar Y, Saşmaz N, Oguz P, Kacar S, Erden E, Parlak E, Akdogan M. Ornidazole-induced autoimmune hepatitis. Eur J Gastroenterol Hepatol 2001; 13: 737-739
162. Kosar Y, Kacar S, Sasmaz N, Oguz P, Turhan N, Parlak E, Heneghan MA, McFarlane IG. Type 1 autoimmune hepatitis in Turkish patients: absence of association with HLA B8. J Clin Gastroenterol 2002; 35: 185-190
163. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23: 116-123
164. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35: 7-13
165. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985; 143: 463-465
166. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-893
167. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-461
168. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-248
169. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-1327
170. Van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, Irish W, Starzl TE. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-776
171. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004; 38: 805-809
172. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-3236
173. Alvarez F, Ciocca M, Cañero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M, Gonzalez T, Jara-Vega P, Camarena C, Brochu P, Drut R, Alvarez E. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 222-227
174. Debray D, Maggiore G, Girardet JP, Mallet E, Bernard O. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135: 111-114
175. Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, González T, López S, Garsd A, Alvarez F. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006; 43: 635-639
176. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110: 271-274
177. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-375
178. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004; 18: 321-326
179. Chatur N, Ramji A, Bain VG, Ma MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee SS, Steinbrecher UP, Yoshida EM. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723-727
180. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005; 39: 819-825
181. Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, Frederick RT, Bonacini M. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802
182. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008; 7: 319-333
183. Hlivko JT, Shiffman ML, Stravitz RT, Luketic VA, Sanyal AJ, Fuchs M, Sterling RK. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-1040
184. Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle PR, Adams DH, Lohse AW. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-3070
185. Oo YH, Neuberger J. Use of mycophenolate in the treatment of autoimmune hepatitis. Liver Int 2005; 25: 687-691
186. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-590
187. Wiegand J, Schüler A, Kanzler S, Lohse A, Beuers U, Kreisel W, Spengler U, Koletzko S, Jansen PL, Hochhaus G, Möllmann HW, Pröls M, Manns MP. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927-934
188. Zandieh I, Krygier D, Wong V, Howard J, Worobetz L, Minuk G, Witt-Sullivan H, Yoshida EM. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol 2008; 22: 388-392
189. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312-1316
190. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485-518
191. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9: 2681-2685
192. Kanzler S, Gerken G, Dienes HP, Meyer zum Büschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997; 35: 571-578
193. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-993
194. Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005; 5: 1085-1089
195. Santos ES, Arosemena LR, Raez LE, O'Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006; 26: 625-629
196. Carmassi F, Morale M, Puccetti R, Pistelli F, Palla R, Bevilacqua G, Viacava P, Antonelli A, Mariani G. Efficacy of intravenous immunoglobulin therapy in a case of autoimmune-mediated chronic active hepatitis. Clin Exp Rheumatol 1992; 10: 13-17
197. Rebollo Bernárdez J, Cifuentes Mimoso C, Piñar Moreno A, Caunedo Alvarez A, Salas Herrero E, Jiménez-Sáenz M, Herrerías Gutiérrez J. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999; 91: 630-638
198. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30: 1381-1386
199. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, Vergani D, Vierling J, Zeniya M. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005; 41: 207-215
200. Heneghan MA, Al-Chalabi T, McFarlane IG. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2006; 7: 145-156
201. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci USA 1998; 95: 12528-12531
202. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum Immunol 2000; 61: 640-650
203. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008; 135: 1953-1960
204. Lohse AW, Dienes HP, Meyer zum Büschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998; 27: 1536-1543
205. Wardrop RM 3rd, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999; 48: 106-119
206. Nagler A, Pines M, Abadi U, Pappo O, Zeira M, Rabbani E, Engelhardt D, Ohana M, Chowdhury NR, Chowdhury JR, Ilan Y. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology 2000; 31: 641-648
207. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96: 1224-1231
208. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006; 43: S132-S144
209. Lapierre P, Béland K, Alvarez F. Pathogenesis of autoimmune hepatitis: from break of tolerance to immune-mediated hepatocyte apoptosis. Transl Res 2007; 149: 107-113
210. Jaeckel E. Animal models of autoimmune hepatitis. Semin Liver Dis 2002; 22: 325-338
211. Christen U, Holdener M, Hintermann E. Animal models for autoimmune hepatitis. Autoimmun Rev 2007; 6: 306-311
212. Bowen DG. Of mice and molecular mimicry: modeling autoimmune hepatitis. Hepatology 2008; 48: 1013-1015
213. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology 2004; 39: 1066-1074
214. Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, Johnson EF, Gonzalez FJ, Pfeilschifter J, Manns MP, Herrath MG, Christen U. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008; 205: 1409-1422
215. Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, Yang VW, Lee OK. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 2008; 134: 2111-2121, 2121.e1-2121.e3